Safety and efficacy study of rhAngiostatin administered in combination with paclitaxel and carboplatin to patients with non-small-cell
lung cancer
This study is currently recruiting patients.
Sponsored by: |
EntreMed |
Information provided by: |
EntreMed |
Purpose
The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with
paclitaxel and carboplatin to patients with non-small-cell lung cancer.
Condition
|
Treatment or Intervention |
Phase |
Carcinoma, Non-Small-Cell Lung
|
Drug: recombinant human Angiostatin protein Drug: paclitaxel Drug: carboplatin
|
Phase II
|
MedlinePlus related topics: Cancer
Study Type: Interventional
Study Design: Treatment
Eligibility
Ages Eligible for Study:
18 Years and above,
Genders Eligible for Study:
Both
Inclusion:
- Histological or cytological confirmed Stage IIIB NSCLC with malignant pleural effusions, or Stage IV NSCLC or recurrent
NSCLC
- No previous chemotherapy for NSCLC
- Have one lesion that is bidimensionally measurable by physical exam, MRI, or CT greater than 1 cm in diameter
- Specified lab parameters
- Life expectancy of at least 12 weeks
- ECOG performance status of 0 or 1
- Understand requirements of study
- Agree to use effective contraceptive methods
Exclusion:
- Have CNS metastases
- Have any active cancer in addition ot NSCLC
- Participated in clinical trial involving conventional or investigational drugs within previous 4 weeks
- Have any contraindication to paclitaxel or carboplatin
- Have had Grade 3 or greater peripheral neuropathies
- Be pregnant or lactating
- Have a history of myocardial infarction or angina pectoris/angina in the last 6 months
- Have had significant (30 mL or more) hemoptysis with the past 3 months
- Have an active infection
- Have a history of bleeding diathesis, hypercoagulable condition, or an active bleeding disorder
- Be receiving concurrent treatment with therapeutic doses of heparin or coumadin
- Have had major surgery within 4 weeks of stating therapy
- Have additional uncontrolled serious medical conditions or psychiatric illness
- Received rhAngiostatin in other clinical protocols
Location
and Contact
Information
Indiana Indiana Cancer Pavilion, Indiana University, Indianapolis,
Indiana,
46202,
United States; Recruiting
Matthew Burns, B.S.
317-278-8247
matburns@iupui.edu
Nasser Hanna, M.D., Principal Investigator
More Information
Study ID Numbers:
ANG-CL-004
Record last reviewed:
November 2002
Record first received:
November 13, 2002
ClinicalTrials.gov Identifier:
NCT00049790Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10